3.4- methylenedioxy-N-methylamphetamine

MDA (3,4-methylenedioxyamphetamine) was available in the 1960 s. The molecule produces empathy in human subjects. In the 1970 s, MDMA(3,4-methylenedioxy-N-methylamphetamine) appeared, followed by MDEA(3,4-methylenedioxy-N-ethylamphetamine) in the 1980 s. All of these molecules were placed in schedule 1 because they were being abused. 

Unlike dopamine, 5-HT is released into the general neuronal regions, not just into synapses, and diffuses over a much larger area to activate neuronal 5-HT receptors. 3,4-Methylenedioxy-N-methylamphetamine (MDMA), cocaine, tricyclic antidepressants, and SSRIs all inhibit the removal of 5-HT from neuronal sites. 

MDMA MDM ADAM ECSTASY 3,4-METHYLENEDIOXY-N-METHYLAMPHETAMINE SYNTHESIS (from MDA) A solution of 6.55 g of... 

For ectasy 3,4-methylenedioxy-N-methylamphetamine, the most commonly reported ADRs occurring in >5% of patienfs using fhe agenf were viral haemorrhagic disease, hypertension, tachycardia, arrhythmias, tachypnoea and hyperthermia [11 ] [12 ] [13 ]. Serotonin syndrome has been associated with the concurrent use of ecstasy and a serotonergic agent [12 ] [13 ]. 

---